Peroxisome proliferator-activated receptors in atherosclerosis and inflammation-An update

Toxicologic Pathology

Volumn 29, Issue 2, 2001, Pages 224-231

  Elangbam, Chandikumar S ^a   Tyler, Ronald D ^b   Lightfoot, Ruth M ^b  

^a Department of Pathology ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adipocyte differentiation; Atherosclerosis; Chemokines; Cytokines; Inflammation; Nuclear receptors; Peroxisome proliferator activated receptors

Indexed keywords

CYTOKINE; GLUCOSE; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ATHEROSCLEROSIS; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; FATTY ACID OXIDATION; FIBRINOLYSIS; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, BROWN; ANIMALS; APOPTOSIS; ARTERIOSCLEROSIS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS; VASCULITIS;

EID: 0034994989     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262301317052495     Document Type: Article

References (79)

1. Antidiabetic characterization of CS-011: A new thiazolidinedione with potent insulin-sensitizing activity
2. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients
3. Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator Troglitazone
4. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor
5. Peroxisome proliferator-activated receptors in the cardiovascular system
6. 2
7. The novel tyrosine-based PPAR-gamma agonist GI262570 shows preferential binding to PPAR-gamma complexed with RXR-alpha and CBP
8. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL-receptor deficient mice
9. Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
10. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPARα, β, and - γ in the adult rat
11. Activated transcription factor nuclear factor-κ B is present in the atherosclerotic lesion
12. Effect of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients
13. PPAR-γ agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression
14. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
15. Troglitazone inhibits atherosclerotic lesion formation and macrophage accumulation in male LDLR-/- mice fed high fat and high fructose diets
16. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
17. The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity
18. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
19. 4pathway to inflammation control
20. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice
21. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
22. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
23. 12, 14prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
24. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels in HDL cholesterol
25. Troglitazone inhibits angitensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells
26. Mechanisms and clinical effects of thiazolidinediones
27. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
28. Peroxisome and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype
29. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
30. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
31. Expression of peroxisome proliferator-activated receptor α (PPAR-α) in primary cultures of human vascular endothelial cells
32. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
33. Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial cells: A possible role for PPAR gamma in endothelial function
34. Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
35. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
36. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
37. Expression and function of PPAR-γ in rat and human vascular smooth muscle cells
38. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
39. Activation of PPARδ alters lipid metabolism in db/db mice
40. Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-κB activity
41. PPARδ functions as a prostacyclin receptor in blastocyst implantation
42. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ
43. Ligand selectivity of the peroxisome proliferator-activated receptor alpha
44. Clinical significance of proliferator-activated receptors in health and disease
45. PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-γ as a potential mediator in vascular disease
46. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T-cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
47. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
48. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
49. CLX-0921: A new PPAR-gamma agonist anti-diabetic thiazolidinedione compound
50. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha
51. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions
52. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency
53. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type-2 diabetes
54. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima fatty rats
55. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
56. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells
57. CLX-0901: A new class of orally active anti-diabetic compound
58. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ
59. NIP-221 is a novel and potent thiazolidinedione-based peroxisome proliferator-activated receptor (PPAR) gamma ligand with long biological half-time
60. Fibrous cap formation or destruction - The critical importance of vascular smooth muscle proliferation, migration, and matrix formation
61. Liver-specific catalase expression in transgenic mice inhibits NF-kappa B activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate
62. Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells
63. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
64. Atherosclerotic plaque rupture: Emerging insights and opportunities
65. The antidiabetic effects of CI-1037/CS011, a new thiazolidinedione
66. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice
67. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
68. WY-14 643 rapidly activates nuclear factor kappaB in kupffer cells before hepatocytes
69. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells
70. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative
71. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocyte THP-1 cells
72. Troglitazone
73. Regulation of apo A-1 gene expression by fibrates
74. Mechanism of action of fibrates on lipid and lipoprotein metabolism
75. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARβ activators
76. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
77. Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: A serial intravascular ultrasound study
78. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo
79. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL